Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The management of patients with chronic respiratory diseases have become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species, and non-tuberculous Mycobacteria (NTM). To overcome these challenges scientists are developed a noval drug formulation of antimicrobial agent and deliver drugs to the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. The important application of inhaling antibiotics is to maximize drug delivery to the target site of infection i.e. the airways and limit the potential for systemic side effects.
The global inhaled antibiotics market size was valued at US$ 1,094.6 million in 2019 and is expected to exhibit a CAGR of 6.3% over the forecast period (2020–2027).
Figure 1: Global Inhaled Antibiotics Market Value (US$ Mn), by Region, 2020
Increasing incidence of respiratory diseases is expected to drive the market growth over the forecast period
Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis is expected to drive the market growth over the forecast period.
According to the World Health Organization Report May 2020, asthma is the most common chronic disease among children worldwide and around 339 million people were living with asthma in 2016. Similarly, according to the same source, over 80% of asthma-related deaths occur in low-and lower-middle income countries.
Inhaled Antibiotics Market Report Coverage
||Market Size in 2019:
||US$ 1,094.6 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 1,784.9 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Product Type: Aerosol, Dry Powder Formulation, Spray.
- By Application: Pneumonia, Asthma, Bronchitis, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, and Pharmaxis Ltd.
- The increasing incidence of chronic respiratory disorders
- The increasing research and development activities for development of noval products
- The increasing adoption of inorganic growth strategies by key players operating in the market The increasing adoption of inorganic growth strategies by key players operating in the market
|Restraints & Challenges:
- Side effects allied with drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions
Moreover, according to the World Health organization 2017 report, around 251 million cases of chronic obstructive pulmonary diseases were found globally in 2016 and around 3.17 million deaths were caused by chronic obstructive pulmonary diseases in 2015. Similarly, according to the same source, more than 90% of COPD deaths occur in low and middle income countries.
Figure 2: Global Inhaled Antibiotics Market Share (%), by Product Type, (2020-2027)
Increasing new product launches and approvals is expected to drive the market growth over the forecast period
Key players operating in the global market are focusing on novel product launches, in order to expand their product portfolio and increase their presence in the global market.
For instance, in October 2017, Polyphor, a Swiss specialty pharmaceutical company, launched an inhaled form of the investigational antibiotic murepavadin (POL7080). Murepavadin, a type of outer membrane protein targeting antibiotic (OMPTA), acts specifically against the bacterial strain Pseudomonas aeruginosa, which is a strain found in patients with several lung diseases, including cystic fibrosis- and non-cystic fibrosis-associated bronchiectasis.
In February 2016, Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., received approval from Health Canada for the application of its generic version of PrTeva-Tobramycin Inhalation Solution. This respiratory antibiotic is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
Moreover, in April 2016, Raptor Pharmaceutical Corp., a biopharmaceutical company, launched its QUINSAIR (levofloxacin inhalation solution) in Germany and Denmark. It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections caused due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).
Global Inhaled Antibiotics Market - Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries across the globe with the World Health Organization declaring it a public health emergency. For instance, according to the World Health Organization report, as of May 15, 2020, there are 4,307,287 individuals affected with coronavirus, globally. The global impact of the coronavirus disease 2019 (COVID-19) has already begun to affect everyone and will significantly affect the inhaled antibiotics market in 2020. Increasing incidence of COVID-19 can affect the global economy by directly affecting production and demand for the products, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
Inhaled Antibiotics Market Restraint
However, side effects associated with drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions may hinder growth of the market.
Major players operating in the global inhaled antibiotics market include Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, and Pharmaxis Ltd.